Financings Of The Fortnight Considers The Value Of Insider Participation In Biotech IPOs
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Radius Health, Cempra, Ironwood and Acetylon.
You may also be interested in...
Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public
Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.
Second Tranche Of $91 Million Venture Round Will Help Advance Two Formulations Of Radius’ Osteoporosis Drug
Radius, which reverse-merged into a public company this past May, has advanced an injectable formulation of BA058 into Phase III, while it is preparing to move a transdermal version into Phase II.